Immunovia announces financial calendar for financial year 2024

                                                                        Year-End 2023 Report                                       February 21, 2024                                                                                    Annual Report to be published                                     March 15, 2024                                                                                    Q1 Report, 2024 ...

                                   

Year-End 2023 Report

                                   

 

February 21, 2024                                   

                                               

Annual Report to be published

                                   

March 15, 2024                                   

                                               

Q1 Report, 2024

                                   

April 25, 2024                                   

                                               

Q2 Report, 2024

                                   

August 22, 2024                                   

                                               

Q3 Report, 2024

                                   

November 14, 2024                                   

                                   

For more information, please contact:

Karin Almqvist Liwendahl

Chief Financial Officer

karin.almqvist.liwendahl@immunovia.com

+46 709 11 56 08

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer.

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com

The following files are available for download:

View original content:https://www.prnewswire.co.uk/news-releases/immunovia-announces-financial-calendar-for-financial-year-2024-302026475.html